The arrhythmia research laboratories in the Knight Cardiovascular Institute investigate arrhythmia mechanisms and treatments across the spectrum from bench to bedside. Our program includes basic scientists, translational researchers, and clinical investigators as well as clinical arrhythmia specialists. We work to elucidate mechanisms of arrhythmias, to develop new treatments, and to improve care and outcomes for all patients. Current projects of interest include:
- Development of novel electrocardiographic markers of the risk of cardiac arrhythmias.
- Prediction and prevention studies of ventricular arrhythmias, atrial fibrillation and sudden cardiac arrest.
- Development and pre-clinical testing of novel arrhythmia ablation devices.
- Pharmaceutical compositions and methods to treat long QT syndrome.
- Cardiac nerve regeneration therapies that can normalize electrical activity and prevent arrhythmias in heart attack survivors.
- Multiple clinical trials for the treatment of arrhythmia.
A particular focus of the Tereschenko lab is subclinical atrial arrhythmias, the burden on elderly and its association with clinical outcomes.
Ventricular Arrhythmia and Sudden Cardiac Death
Our researchers are working to investigate the underlying mechanisms of ventricular arrhythmias and sudden cardiac death, as well as develop novel biomarkers for diagnostic and therapeutic application. Of special interest to the Habecker lab is the role of the nervous system in triggering arrhythmias and potential targets for treatment and prevention.
Diagnostic and Ablation Technologies
Our labs are focused on developing novel ablation methods and devices for the treatment of cardiac arrhythmias, particularly ventricular tachycardia (VT). Dr. Nazer has worked to develop high-intensity focused ultrasound (HIFU) catheters, which use acoustic energy for arrhythmia ablation. He collaborates with Acoustic Physics, Biomedical Engineering and industry colleagues to further develop these tools and others. Dr. Tereshchenko is working to develop a risk score of sudden cardiac death for clinical application.
Under way is a clinical study among patients with frequent premature ventricular complexes (PVCs) that involves a simple, diagnostic echocardiogram to help predict the risk of PVC-induced cardiomyopathy.
Additional trials include:
Randomized Controlled Trial “Adaptive CRT Effect on Electrical Dyssynchrony” (aCRT-ELSYNC) NCT02543281: The purpose of this study is to better understand how adaptive cardiac resynchronization therapy (aCRT) might benefit patients.
Case-control study “Hypertrophic Cardiomyopathy Pilot Study” NCT02806479:This study evaluates mechanisms of arrhythmogenicity in hypertrophic cardiomyopathy, in comparison to patients with well-understood arrhythmogenic substrate (ischemic cardiomyopathy), as well as to individuals free from arrhythmogenic substrate.
Cohort study “Assessment of S-ICD Eligibility with 12-Lead ECG (EL-SID)”:The objective of this observational cohort study is to determine eligibility for subcutaneous ICD implantation based on 12-lead ECG analysis.
Postdoctoral and other research positions are available within the arrhythmia research laboratories of the Knight Cardiovascular Institute. Please review ourfaculty profiles below for further information about areas of focus and contactthe faculty member directly to inquire about available positions associatedwith his or her laboratory.
For more information
Email email@example.com to:
- Partner on our research
- Inquire about postdoctoral positions
Call 503-418-1964 to:
Inquire about actively enrolling cardiovascular clinical trials.